Ads
related to: aromatase inhibitor for bodybuilders- Stagnation In 1L ET
Rethink Endocrine Therapy.
Learn More About Approaches.
- Limitations Of 1L AI
Endocrine Resistance Can Result In
Earlier Progression On 1L Treatment
- Time On 1L Matters
Time On 1L May Improve Long-Term
Survival. Find Out More.
- Rethink 1L ET
Modernize Your Understanding Of
What Is Limiting Patients' Time.
- Stagnation In 1L ET
Search results
Results From The WOW.Com Content Network
1,4,6-Androstatriene-3,17-dione (ATD) is a potent irreversible aromatase inhibitor that inhibits estrogen biosynthesis by permanently binding and inactivating aromatase in adipose and peripheral tissue. [1] It is used to control estrogen synthesis. [2]
[7] [1] In any case, AG is also used by bodybuilders and other men for its actions as an aromatase inhibitor in order to decrease estrogen levels. [7] It is said to be useful for inhibiting the estrogenic side effects of certain anabolic steroids such as gynecomastia , increased water retention , and fat gain .
Ovarian stimulation with the aromatase inhibitor letrozole has been proposed for ovulation induction in order to treat unexplained female infertility. In a multi-center study funded by the National Institute of Child Health and Development, ovarian stimulation with letrozole resulted in a significantly lower frequency of multiple gestation (i.e., twins or triplets) but also a lower frequency ...
Anabolic steroids used to increase muscle mass and strength can disrupt the natural function of the hypothalamic-pituitary-testicular hormonal axis. ... or aromatase inhibitors like anastrozole ...
[4] [5] [6] Aromatase is responsible for the conversion of testosterone to estradiol. Blocking aromatase causes the body to decrease in levels of estradiol, which then results in increase of LH and consequently, testosterone. Since testosterone has myotropic activity and estradiol does not, elevated testosterone levels increase muscle mass.
Because of these natural hormone-hormone interdependent biosynthetic pathways and hormone-receptor interactions, all aromatase inhibitors, including anastrozole, letrozole, aminoglutethimide, exemestane, formestane, and testolactone are banned. Selective estrogen receptor modulators, including raloxifene, tamoxifen and toremifene are banned.